Nutranomics, Inc.
Nutranomics, Inc.
Your view on NNRX
Overview
What the company does, where it operates, and who runs it.
About Nutranomics, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jonathan Bishop
- Headquarters
- 11487 South 700 East, Salt Lake City, UT, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jonathan Bishop
- Headquarters
- 11487 South 700 East, Salt Lake City, UT, US
Nutranomics, Inc. engages in the research, development, and sale of nutritional food products. It offers approximately 480 nutritional supplements, including formulating vitamin, mineral, herbal, and probiotic supplements.
The company provides Nutritional Blood Analysis, a tool to examine the customer's blood cells on a video monitor, live, in real time; and the patented Assimilation Enhancing System that improves the absorption of nutrients.
In addition, it offers educational services, including various types of analyses, trainings, certifications, and group presentations to individuals and industry professionals.
The company distributes its products through sales representatives throughout North America and Asia, as well as through retail stores. Nutranomics, Inc. has a strategic partnership with Terra-Formance, LLC. The company was founded in 1995 and is headquartered in Salt Lake City, Utah.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nutranomics, Inc., and the rating behind it. NNRX last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nutranomics, Inc.. Starting points for Nutranomics, Inc.: beta -0.02 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nutranomics, Inc.. Nutranomics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nutranomics, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nutranomics, Inc.. Nutranomics, Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nutranomics, Inc. valued side by side against its closest peers. Nutranomics, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nutranomics, Inc., and how their positions are changing. At a $816,232 market value, institutional positions materially move Nutranomics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nutranomics, Inc. executives and directors. Shares of Nutranomics, Inc. have traded between $0.0001 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nutranomics, Inc.. Nutranomics, Inc. is a $816,232 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nutranomics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nutranomics, Inc.. Coverage tracks Nutranomics, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.